Data Up to Date as of:
On This Page:
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. The first targeted therapy for bladder cancer was approved by the FDA in 2019. Treatment options depend on the stage of bladder cancer. Four types of standard treatment are used: surgery, radiation therapy, chemotherapy, and immunotherapy. Intravesical (within the bladder) therapy, one type of immunotherapy, involves the instillation of an agent or biologic into the bladder. The use of intravesical therapy has been associated with improved survival for individuals with non-muscle invasive bladder cancer. There has been a significant increase in the use of intravesical therapy for patients diagnosed with non-muscle invasive Ta G1-2 bladder cancer. The Ta G1-2 means non-invasive papillary carcinoma (Ta) that is Grade 1 (well differentiated) or Grade 2 (moderately differentiated).
Percentage of individuals receiving intravesical therapy in non-muscle invasive bladder cancer.
Healthy People 2030 Target
- There are no Healthy People 2030 targets for cancer treatment, including bladder cancer treatment.
Healthy People 2030 is a set of goals set forth by the Department of Health and Human Services.
SEER Patterns of Care/Quality of Care Studies, National Cancer Institute, 1995-2009.
|Overview Graph||Detailed Trend Graphs||Most Recent Estimates (2009)|
|Percent of patients||95% Confidence Interval|
|Ta G1-2||29.7||(22.3 - 37.1)|
|Other non-muscle invasive disease||39.9||(31.2 - 48.6)|
Additional Information on Bladder Cancer Treatment
- Bladder Cancer Treatment (PDQ®)-Health Professional Version. National Cancer Institute.